Singapore markets closed

STAAR Surgical Company (STAA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
45.54+0.85 (+1.90%)
At close: 04:00PM EDT
45.60 +0.06 (+0.13%)
After hours: 05:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close44.69
Open45.46
Bid45.43 x 100
Ask45.57 x 100
Day's range44.38 - 45.78
52-week range26.66 - 68.27
Volume401,041
Avg. volume720,127
Market cap2.237B
Beta (5Y monthly)0.88
PE ratio (TTM)105.91
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

    LAKE FOREST, Calif., May 01, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.

  • Business Wire

    STAAR Surgical to Report First Quarter Results on May 7, 2024

    LAKE FOREST, Calif., April 29, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

  • Business Wire

    STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

    LAKE FOREST, Calif., April 04, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company